Aerie pharmaceuticals receives european commission approval for roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the european commission (ec) has granted a marketing authorisation for roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intraocu
AERI Ratings Summary
AERI Quant Ranking